Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan 16;21(1):23.
doi: 10.1186/s13075-019-1809-y.

Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II)

Dinesh Khanna  1   2 , Philip J Clements  3 , Elizabeth R Volkmann  3 , Holly Wilhalme  3 , Chi-Hong Tseng  3 , Daniel E Furst  3 , Michael D Roth  3 , Oliver Distler  4 , Donald P Tashkin  3
Affiliations

Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II)

Dinesh Khanna et al. Arthritis Res Ther. .

Abstract

Objective: This study aimed to assess the minimal clinically important differences (MCIDs) for the modified Rodnan skin score (mRSS) using combined data from the Scleroderma Lung Studies (I and II).

Methods: MCID estimates for the mRSS at 12 months were calculated using three anchors: change in scores on the Health Assessment Questionnaire- Disability Index from baseline to 12 months, change in scores on the Patient Global Assessment from baseline to 12 months, and answer at 12 month for the Short Form-36 health transition question "Compared to one year ago, how would you rate your health in general now?" We determined the mRSS MCID estimates for all participants and for those with diffuse cutaneous systemic sclerosis (dcSSc). We then assessed associations between MCID estimates of mRSS improvement and patient-reported outcomes, using Student's t test to compare the mean differences in patient outcomes between those who met the MCID improvement criteria versus those who did not meet the improvement criteria.

Results: The mean (SD) mRSS at baseline was 14.75 (10.72) for all participants and 20.93 (9.61) for those with dcSSc. The MCID estimate for mRSS improvement at 12 months ranged from 3 to 4 units for the overall group (improvement of 20-27% from baseline) and was 5 units for those with dcSSc (improvement of 24% from baseline). Those who met the mRSS MCID improvement criteria had statistically significant improvements in scores on the Short Form-36 Physical Component Summary, the Transition Dyspnea Index, and joint contractures at 12 months.

Conclusion: MCID estimates for the mRSS were 3-4 units for all participants and 5 units for those with dcSSc. These findings are consistent with previously reported MCID estimates for systemic sclerosis.

Trial registration: ClinicalTrials.gov NCT00004563 NCT00883129.

Keywords: Interstitial lung disease; Minimal clinically important difference; Modified Rodnan skin score; Scleroderma; Skin thickness; Systemic sclerosis.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

The study protocols for both SLS-I and II were approved by the local Institutional Review Boards, and written informed consent was obtained from all participants.

Consent for publication

Not applicable.

Competing interests

Boehringer Ingelheim was not involved in directing the content of the manuscript and was only given the opportunity to review the manuscript for factual accuracy.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

    1. Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685-169. - PubMed
    1. Khanna D, Furst DE, Clements PJ, Allanore Y, Baron M, Czirjak L, Distler O, Foeldvari I, Kuwana M, Matucci-Cerinic M, et al. Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. J Scleroderma Relat Disord. 2017;2(1):11–18. doi: 10.5301/jsrd.5000231. - DOI - PMC - PubMed
    1. Hays RD, Woolley JM. The concept of clinically meaningful difference in health-related quality-of-life research. How meaningful is it? Pharmacoeconomics. 2000;18(5):419–423. doi: 10.2165/00019053-200018050-00001. - DOI - PubMed
    1. Revicki D, Hays RD, Cella D, Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol. 2008;61(2):102–109. doi: 10.1016/j.jclinepi.2007.03.012. - DOI - PubMed
    1. Khanna D, Furst DE, Hays RD, Park GS, Wong WK, Seibold JR, Mayes MD, White B, Wigley FF, Weisman M, et al. Minimally important difference in diffuse systemic sclerosis: results from the d-penicillamine study. Ann Rheum Dis. 2006;65(10):1325–1329. doi: 10.1136/ard.2005.050187. - DOI - PMC - PubMed

Publication types

MeSH terms

Associated data